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Purpose: To understand the expression of genes involved in different complement pathways in the retina and retinal
pigment epithelium (RPE)/choroid under physiologic conditions and how their expression is regulated by inflammatory
cytokines.
Methods: The expression of complement components of the classical pathway (CP), mannose-binding lectin (MBL)
pathway, alternative pathway (AP), and terminal pathway in the retina and RPE/choroid was determined by conventional
reverse transcription polymerase chain reaction (RT–PCR). The effect of inflammatory cytokines, tumor necrosis factor-
alpha (TNF-α, 20 ng/ml), interleukin (IL)-6 (10 ng/ml), interferon-gamma (IFN-γ, 100 ng/ml) or lipopolysaccharides
(LPS, 1 μg/ml) on the expression of these complement component genes was tested in vitro in primary cultured RPE cells
and a microglial cell line (BV2 cells) and quantified by real-time RT–PCR.
Results: In the CP, complements C1qb, C1r, C1s, C2, and C4 were constitutively expressed by retina and RPE/choroid.
Complement factor H and factor B of the AP as well as C3 were also detected in the retinal and RPE/choroidal tissues.
In the MBL pathway, low levels of mannose-binding lectin (MBL)-associated serine protease (MASP)-1 in the retina and
RPE/choroid and MASP2L in the retina were detected. Other components, including mannose-binding lectin 1 (MBL1),
mannose-binding lectin 2 (MBL2), complement factor I (CFI), complement component 5 (C5) and complement factor H-
related protein 1 (CFHR1), were not detected in either the retina or the RPE/choroid. The expression of CP- and AP-
complement component genes in RPE and microglial cells was upregulated by interferon (IFN)-γ treatment. Treatment
with TNF-α selectively upregulated the expression of C1s and C3 genes but downregulated complement factor H gene
expression in RPE and microglial cells. The expression of genes involved in the MBL pathway was not affected by the
inflammatory cytokines tested in this study.
Conclusions: Retina and RPE/choroid express a variety of complement components that are involved mainly in the CP
and AP. RPE and microglial cells are the main sources of retinal complement gene expression. Retinal complement gene
expression is regulated by inflammatory cytokines, such as IFN-γ and TNF-α.
The retina is segregated from the circulation by the blood
retinal barrier and is considered to be an immune “privileged”
tissue. It is, however, still under the surveillance of the innate
immune  system  by  specialized  myeloid-derived  cells,
including microglia [1,2], perivascular macrophages [1,2] and
a novel population of dendritic cells that express 33D1 and
major  histocompatibility  complex  class  II  molecules  [3].
Under normal physiologic conditions, these cells are in a
“quiescent”  state  but  are  able  to  sense  exogenous  and
endogenous danger stimuli. Once engaged with these signals,
the cells are activated, resulting in retinal inflammation [4].
In addition to myeloid-derived cells, compelling evidence
suggests that proteins of the complement system also exist in
the retina [5-8], which together comprise the retinal innate
immune system.
Activation of the retinal innate immune system (e.g.,
microglia and the complement system) has been shown to be
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involved not only in retinal diseases with overt inflammation,
such as uveoretinitis [9-11], but also in a variety of retinal
degenerative  diseases,  including  age-related  macular
degeneration  [5,12-14],  diabetic  retinopathy  [15,16],  and
glaucomatous retinopathy [17]. Modulating retinal immune
activation provides a novel therapeutic approach to control
these pathological conditions. The roles of retinal microglia/
macrophages in various retinal diseases have been extensively
studied  [4].  However,  our  knowledge  on  the  retinal
complement system, such as which complement components
are  expressed  in  the  retina  and  how  their  expression  is
regulated, remains limited.
The complement system can be activated through the
classical pathway (CP), the alternative pathway (AP), and the
mannose-binding  lectin  (MBL)  pathway.  In  addition,
complement  can  also  be  activated  independently  of
complement component 3 (C3) by a direct action of thrombin
on the C5 convertase [18]. All pathways of the complement
system lead to formation of the cytolytic membrane attack
complex. The complement system consists of over 25 proteins
and  protein  fragments,  and  different  activation  pathways
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1588require contributions from different proteins. Complement
proteins are generally synthesized in the liver by hepatocytes
and  released  as  inactive  precursors  (proproteins)  into  the
blood for tissue distribution. Under pathological conditions in
which the blood retinal barrier breaks down, complement
proteins  may  leak  into  retinal  tissue,  resulting  in  local
complement activation. However, recent work from our group
and others has shown that certain complement components,
such as complement component 1q (C1q) [6,19], C3 [6,19],
and complement regulatory factors (e.g., factor H (CFH) [6,
20],  factor  B  (CFB)  [6,21],  CD59  [7,22]),  can  also  be
synthesized locally by retinal cells, suggesting that de novo
complement production may contribute to its activation in this
setting.
The present study was undertaken to investigate the gene
expression of key proteins involved in the CP, AP, and MBL
pathways of the complement system in the retina and retinal
pigment  epithelium  (RPE)/choroid  under  physiologic
conditions. We also aimed to understand the sources of these
complement proteins and how their expression is regulated by
inflammatory cytokines.
METHODS
Animals: C57BL/6 mice (8–12 weeks of age) were purchased
from Harlan Laboratories Ltd. (Oxon, UK) and maintained in
the Biologic Resource Unit at Queen’s University Belfast.
Postnatal day 14 C57BL/6 mice were supplied by the Biologic
Resource Unit at Queen’s University Belfast. All mice were
housed in a standard experimental room and exposed to a 12
h:12  h  light–dark  cycle.  The  study  was  conducted  in
compliance with the Association for Research in Vision and
Ophthalmology  statement  for  the  Use  of  Animals  in
Ophthalmic and Vision Research, and all animal experiments
were  performed  under  the  regulations  of  the  UK  Animal
License Act 1986.
Sample collection: Retinal and RPE/choroidal tissues were
collected from adult (8–12 weeks of age) C57BL/6 female
mice. Mice were sacrificed with CO2 inhalation; eyes were
carefully enucleated and further dissected under a surgical
microscope. The anterior segment of the eye including the
cornea, iris, and the lens were removed; retinas were peeled
off from RPE/choroid. Retina, RPE/choroid, and liver tissue
samples were snap frozen in liquid nitrogen for further RNA
extraction.
Cell cultures: Primary mouse RPE cells were isolated and
cultured from C57BL/6 mice using a previously described
method  with  slight  modifications  [23,24].  In  brief,  after
removing the anterior segment of the eye and the lens, the
eyecups were incubated with 0.5% (weight [w]/volume [v])
trypsin-EDTA (ICN Flow, Irvine, UK) at 37 °C for 1 h. The
cells were then harvested by gentle aspiration, and single-cell
suspensions were seeded into culture dishes with Dulbecco’s
Modification  of  Eagle’s  Medium  (DMEM;  Gibco  BRL,
Paisley, UK) containing 10% (v/v) fetal calf serum (FCS;
Sigma, Cambridge, UK) and 100 µg/ml primocin (Invivogen,
San Diego, CA). Upon reaching confluence, RPE cells were
subcultured (1:3 ratio) and their phenotype was confirmed by
RPE65 and cytokeratin staining [25]. The third passage of
RPE cells was used for further experiments. In addition, a
novel mouse RPE cell line, B6-RPE07, established in our
laboratory  was  also  used  in  this  study  and  maintained  in
DMEM with 10% FCS [25].
Retinal  microglial  cells  were  cultured  from  day  14
postnatal C57BL/6 mice using a previously described method
[26]. Briefly, retinas were cut into small pieces and incubated
with 1 mg/ml type I collagenase (Sigma-Aldrich, Dorset, UK),
0.3  mg/ml  DNase  I  (Sigma-Aldrich),  and  0.2  mg/ml
hyaluronidase (Sigma-Aldrich) at 37 °C for 20 min before the
cell suspension was filtered through a 100-µm cell strainer
(BD Biosciences, Oxford, UK). Cells were then cultured for
10 days in 24-well plates containing DMEM/F12 with 10%
FCS,  supplemented  with  20%  L929-conditioned  medium
containing  M-CSF  [27].  Immunocytochemistry  confirmed
that  approximately  98%  of  the  cells  were  CD11b+  and
approximately 92% were F4/80+.
Brain microglia were cultured from mouse brain tissue
using the same method described above for retinal microglial
cells. A mouse microglial cell line, BV-2 [28], was cultured
in  DMEM  with  10%  FCS  and  100  μg/ml  primocin  and
incubated in 5% CO2 at 37 °C.
Pro-inflammatory  cytokine  treatment:  The  third  passage
mouse RPE cells or BV-2 cells were cultured in 12-well plates
at a density of 3×104 cells/well. After reaching confluence,
cells were washed with PBS (137 mM NaCl, 2.7 mM KCl,
8 mM Na2HPO4 and 1.46 mM KH2PO4 in distilled water,
Ca2+ and Mg2+ free) and treated with TNF-α (20 ng/ml), IL-6
(10  ng/ml),  IFN-γ  (100  ng/ml;  R&D  Systems,  Abingdon,
UK), or LPS (1 µg/ml; Sigma-Aldrich) for 20 h. The cells were
then collected for total RNA extraction. Triplicate samples
were used for each treatment. The concentration of cytokines
used in this experiment was based on our previous experience
with complement gene expression in RPE cells [20,21].
RNA isolation and reverse transcription:  Total RNA was
extracted from tissues or cultured cells using the RNeasy mini
kit  (Qiagen  Ltd.,  West  Sussex,  UK)  according  to  the
manufacturer’s  instructions.  An  RNase-free  DNase  Set
(Qiagen Ltd.) was used for optional DNase treatment. The
quantity and quality of the RNA was determined using a
NanoDrop  ND-1000  spectrophotometer  (NanoDrop
Technologies, Wilmington, DE). First-strand cDNA synthesis
was performed by a reaction of 2.5 µg of total RNA with a
random  primer,  using  the  SuperScript™  II  Reverse
Transcriptase kit (Invitrogen, Paisley, UK).
Conventional  RT–PCR:  Conventional  RT–PCR  was
performed in the retina, RPE/choroidal tissue, or cultured
cells, using the promega GoTaq® Flexi DNA Polymerase kit
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genes was performed for 40 cycles, and PCR products were
observed by agarose gel electrophoresis. Amplifications of
complement  components  in  the  liver  acted  as  positive
controls. The primers were designed using the NCBI Primer-
BLAST and are listed in Table 1.
Real-time reverse transcription (RT)-PCR: Real-time RT–
PCR was performed on a total of 20 µl of mixture solution in
96-well  plates  using  the  LightCycler  480  system  (Roche
Applied  Science,  Mannheim,  Germany).  Each  20  µl  of
reaction mixture contained 10 µl of LightCycler 480 SYBR
Green  Master  (Roche  Diagnostics  GmbH,  Mannheim,
Germany), 0.5µM primers, and diluted cDNA. Real-time PCR
quantifications were run in triplicate for each sample, the
average was determined, and PCR products were quantified
using the LightCylcer 480 software. Melting curve and gel
electrophoretic analyses were used to determine amplification
homogeneity  and  data  quality.  Expression  levels  were
normalized to β-actin. Gene-fold changes of treated versus
untreated control groups were calculated by dividing the gene
expression levels of corresponding samples.
Statistical  analysis:  All  data  were  presented  as  means
±standard  error  of  the  mean.  The  difference  between  the
treated  group  and  control  group  was  compared  using  an
unpaired  Student  t  test,  with  p<0.05  considered  to  be
statistically significant.
RESULTS
Complement  gene  expression  in  mouse  retina  and  retinal
pigment epithelium/choroid.
Classical  pathway—We  examined  the  expression  of
complement C1 subunits (C1qb, C1r, C1s) and complement
components (C2 and C4) genes in this pathway. All of these
genes were found to be expressed in mouse retina and RPE/
choroid (Figure 1A). To further understand which cells might
be the sources of the CP-complement gene expression in retina
TABLE 1. LIST OF PRIMERS USED IN PCR STUDIES.
Entrez ID Gene symbol Primers (5′-3′) Product size
(bp)
12260 C1qb
F: ATAAAGGGGGAGAAAGGGCT
R: CGTTGCGTGGCTCATAGTT
301
50909 C1r
F: GCCATGCCCAGGTGCAAGATCAA
R: TGGCTGGCTGCCCTCTGATG
313
50908 C1s
F: TGGACAGTGGAGCAACTCCGGT
R: GGTGGGTACTCCACAGGCTGGAA
256
12263 C2
F: CTCATCCGCGTTTACTCCAT
R: TGTTCTGTTCGATGCTCAGG
178
12266 C3
F: AGCAGGTCATCAAGTCAGGC
R: GATGTAGCTGGTGTTGGGCT
167
12268 C4
F: ACCCCCTAAATAACCTGG
R: CCTCATGTATCCTTTTTGGA
320
15139 C5
F: AGGGTACTTTGCCTGCTGAA
R: TGTGAAGGTGCTCTTGGATG
173
12630 CFI
F: TTTCCCAACGAGTCTGTCCT
R: TGCAGTCCACCTCACCATTA
194
50702 CFHR1
F: TTCTGGACTCGCATCACTTG
R: AGCCTTGATTGCAGACCACT
157
14962 CFB
F: CTCCTCTGGAGGTGTGAGCG
R: GGTCGTGGGCAGCGTATTG
264
12628 CFH
F: CGTGAATGTGGTGCAGATGGG
R: AGAATTTCCACACATCGTGGCT
248
17194 MBL1
F: AGGGAGAACCAGGTCAAGGGCT
R: ACTGCCCTTCAGTCGCCTCGT
414
17195 MBL2
F: CCCTGCCTGCAGTGACACCA
R: AGCACCCAGTTTCTCAGGGCT
443
17174 MASP1
F: AGGACCTGCCGAGTGGAATG
R: TCTCCACAGAAGGGACCCCA
251
17175 MASP2 isoform 1 (MASP2L)
F: CCTGCAGAGCGGGCTACGTT
R: AGGGCCGTGCTGTGCTTGTG
402
17175 MASP2 isoform 2 (MASP2S)
F: ACTGACTGCACCCCCTGGCT
R: GGGCTGTTGCTGAGGGAGGT
435
11461 ACTB
F: CCTTCCTTCTTGGGTATG
R: TGTAAAACGCAGCTCAGTAA
367
               F: forward; R: reverse
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1590and RPE/choroid, we then examined microglia and RPE cells.
Under normal culture conditions, primary microglial cells
(originated from either mouse retina or brain) and the mouse
microglial cell line (BV-2) expressed all five CP-complement
genes (Figure 1B), suggesting that microglia may be one of
the main sources of CP complement gene expression in the
retina. Primary cultured RPE cells expressed C1r, C1s, C2,
and C4 but not C1qb (Figure 1B), whereas cells of the mouse
RPE cell line B6-RPE07 only expressed C1r, C1s, and C4.
These results suggest that C1qb gene expression detected in
RPE/choroidal  tissue  might  be  attributed  from  choroidal
macrophage/dendritic cells and that the B6-RPE07 cells may
have  lost  C2  gene  expression  during  prolonged  in  vitro
culture.
Mannose-binding lectin (MBL) pathway—Five genes
of this pathway, including two receptors (MBL1 and MBL2)
and  three  MBL-associated  serine  protease  (MASP)  genes
(MASP-1, MASP2L, and MASP2S), were examined. Weak
expressions of MASP1 in the retina and RPE/choroid and of
MASP2L in the retina were detected (Figure 2A). Neither the
retina nor the RPE/choroid expressed detectable levels of
MBL-1,  MBL-2,  and  MASP2S  genes  (Figure  2A).  Under
normal culture conditions, the expression of the MASP1 gene
was detected in RPE and primary cultured microglial cells
(Figure 2B). Although a low level of MASP2L was detected
in the retina, microglial cultures did not express detectable
levels of this gene (Figure 2B).
Alternative pathway—In the AP, CFH and CFB are
strongly expressed in both retina and the RPE/choroid (Figure
3A).  In  contrast,  neither  the  retina  nor  the  RPE/choroid
expressed  detectable  levels  of  CFH-related  protein-1
(CFHR1) and complement factor I (CFI) genes (Figure 3A).
We  have  shown  previously  that  CFH  and  CFB  are
produced by RPE cells [20,21], and this was further confirmed
in this study. Both primary cultured RPE cells and the mouse
RPE cell line B6-RPE07 expressed high levels of CFH and
CFB (Figure 3B). In addition, primary cultured microglial
cells and BV-2 cells also expressed high levels of CFH and
CFB  (Figure  3B).  Neither  RPE  cells  nor  microglial  cells
Figure 1. The expression of selected classical pathway-related complement genes. The expression of C1qb, C1r, C1s, C2, and C4 in retina
and retinal pigment epithelium (RPE)/choroid (A) and primary cultured RPE cells, B6-RPE07 cell line, primary cultured retinal microglia
(Ret_microglia), brain microglia (Bri_microglia), and BV-2 cells (B) were analyzed by reverse transcriptase-PCR. Total RNA from mouse
liver tissue was used as a positive control.
Figure 2. The expression of selected mannose binding lectin (MBL) pathway-related complement genes. The expression of MBL1, MBL2,
MASP1, MSAP2L, and MASP2S in retina and RPE/choroid (A) and primary cultured retinal pigment epithelium (RPE) cells, B6-RPE07 cell
line, primary cultured retinal microglia (Ret_microglia), brain microglia (Bri_microglia), and BV-2 cells (B) were analyzed by reverse
transcriptase-PCR. Total RNA from mouse liver tissue was used as a positive control.
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1591express detectable levels of CFHR1 and CFI under normal
culture conditions (Figure 3B).
C3 and C5 genes—Complement C3 and C5 are essential
for the full activation of the complement system in all three
pathways. Interestingly, C3 but not C5 is expressed in the
retinal and RPE/choroidal tissues (Figure 4A) as well as in
cultured RPE and microglial cells (Figure 4B).
The effect of inflammatory cytokines on complement gene
expression:  Having  shown  that  retinal  and  RPE/choroidal
tissues  express  genes  involved  in  the  CP,  AP,  and  MBL
pathway  under  normal  physiologic  conditions  and  that
microglial and RPE cells are the major sources of complement
gene expression in the retina and RPE/choroid, we then sought
to understand how expression of these genes may be affected
under  inflammatory  conditions.  Cultured  mouse  RPE  and
microglial  cells  were  treated  with  three  inflammatory
cytokines: TNF-α, IFN-γ, and IL-6. In addition, the endotoxin
LPS was used as a positive control for inflammatory stimuli.
Complement gene expression was quantitatively analyzed by
real-time RT–PCR. For microglia we used a stabilized cell
line BV-2. For RPE cells we used primary cultured mouse
RPE cells as the mouse RPE cell line B6-RPE07 has been
shown to have lost the expression of some of the complement
genes (e.g., C2, Figure 1).
Classical pathway complement gene expression: Among the
three  pro-inflammatory  cytokines,  IFN-γ  strongly
upregulated  expression  of  all  CP-related  genes  in  both
microglial cells (Figure 5A) and RPE cells (Figure 5B). The
highest upregulation was observed in the C2 gene in RPE
cells, which showed over an 80 fold increase upon 100 ng/ml
IFN-γ treatment (Figure 5B). TNF-α significantly increased
C1s gene expression in BV-2 cells (Figure 5A) and C1r,
C1s, and C2 gene expression in RPE cells (Figure 5B). Apart
from C1qb, which was upregulated by IL-6 in BV-2 cells, all
other CP-related genes were not affected by IL-6 (Figure 5).
Treatment with LPS upregulated the expression of C1s in
BV-2 cells (Figure 5A) and C1s and C1r genes in RPE cells
(Figure 5B).
C1qb gene expression was not detected in RPE cells
under normal culture conditions (Figure 1B) and was not
induced  by  treatment  with  a  range  of  different  pro-
inflammatory cytokines or LPS (Figure 5C).
MBL pathway related complement gene expression: In the
MBL pathway, MASP1 but not MBL1, MBL2, or MASP2S
was  detected  in  cultured  RPE  cells  (Figure  2B).  The
expression  of  MBL-related  genes  in  RPE  cells  was  not
affected  by  either  LPS  or  any  of  the  pro-inflammatory
cytokine treatments (Figure 6A,B). BV-2 cells did not express
Figure 3. The expression of selected alternative pathway-related complement genes. The expression of CFI, CFH, CFB, and CFHR1 in retina
and retinal pigment epithelium (RPE)/choroid (A) and primary cultured RPE cells, B6-RPE07 cell line, primary cultured retinal microglia
(Ret_microglia), brain microglia (Bri_microglia), and BV-2 cells (B) were analyzed by reverse transcriptase-PCR. Total RNA from mouse
liver tissue was used as a positive control. CFH, complement factor H; CFB, complement factor B; CFI, complement factor I CFHR1,
complement factor H-related protein 1.
Figure 4. The expression of complement C3 and C5 genes. The expression of C3 and C5 in retina and retinal pigment epithelium (RPE)/
choroid (A) and primary cultured RPE cells, B6-RPE07 cell line, primary cultured retinal microglia (Ret_microglia), brain microglia
(Bri_microglia), and BV-2 cells (B) were analyzed by reverse transcriptase-PCR. Total RNA from mouse liver tissue was used as a positive
control.
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conditions (Figure 2B), and treatment of the cells with pro-
inflammatory  cytokines  or  LPS  also  did  not  induce  the
expression of any of these genes (Figure 6B).
Alternative pathway (AP) complement gene expression: We
have previously shown that inflammatory cytokines (TNF-α,
IFN-γ, and IL-6) downregulate CFH gene [20] but upregulate
CFB gene [21] expression in RPE cells. In the present study
in  BV-2  cells,  CFH  expression  was  downregulated  by
treatment with TNF-α and LPS but upregulated by IFN-γ
(Figure 7A). The expression of CFB in BV-2 cells was not
affected by TNF-α but was massively upregulated by IFN-γ
and LPS (Figure 7A).
CFI and CFHR1 genes were not expressed in microglia
or  RPE  cells  under  normal  culture  conditions  (Figure  3).
Treatment of the cells with TNF-α, IFN-γ, IL-6, or LPS did
not induce the expression of these genes (Figure 7B).
Complement C3 and C5 gene expression: Complement C3
was constitutively expressed by microglial and RPE cells
(Figure 3A), and the levels were further enhanced by TNF-α
and LPS treatment (Figure 8A). IFN-γ also increased C3 gene
expression in BV-2 cells (Figure 8A). C3 gene expression in
RPE cells was not affected by IFN-γ (Figure 8A).
The C5 gene was not expressed in microglia or RPE cells
under normal culture conditions (Figure 4), and treatment of
cells with inflammatory cytokines or LPS did not induce its
expression (Figure 8B).
DISCUSSION
Here, we show that murine retina and RPE/choroid express
key complement components involved in the CP and AP and
Figure 5. The effect of inflammatory cytokine on classical pathway-related complement gene expression in BV-2 and retinal pigment
epithelium cells. BV-2 cells (A) and primary cultured mouse RPE cells (B, C) were treated with tumor necrosis factor (TNF)-α (20 ng/ml),
interleukin (IL)-6 (10 ng/ml), interferon (IFN)-γ (100 ng/ml), or lipopolysaccharides (LPS; 1µg/ml) for 20 h. Cells were then collected for
real-time RT–PCR (A, B) or conventional RT–PCR (C). Mouse liver RNA was used as a positive control in C. n=3 in each group. *p<0.05;
**p<0.01; ***p<0.001 as compared to untreated control group using unpaired Student's t-test. Experiments were repeated twice.
Figure 6. The effect of inflammatory cytokine on mannose binding lectin pathway-related complement gene expression in BV-2 and retinal
pigment epithelium cells. Primary RPE cells and BV-2 cells were treated with pro-inflammatory cytokines tumor necrosis factor (TNF)-α
(20 ng/ml), interferon (IFN)-γ (100 ng/ml), interleukin (IL)-6 (10 ng/ml), and lipopolysaccharides (LPS; 1 µg/ml) for 20 h. Cells were then
collected for real-time RT–PCR (A) or conventional RT–PCR (B, C). Mouse liver RNA was used as a positive control in B and C. n=3 in
each group. Experiments were repeated twice.
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1593that retinal microglia and RPE cells are the major sources of
complement gene expression. Furthermore, we demonstrated
that the expression of retinal complement protein/regulatory
factors is regulated by inflammatory cytokines, such as IFN-
γ and TNF-α. In relation to the MBL pathway, only a low level
of MASP2L expression in retina and MASP1 expression in
retinal  and  RPE/choroidal  tissues  was  detected,  and  their
expression in RPE or microglial cells was not affected by
inflammatory cytokines. Our results suggest that the CP and
AP but not the MBL pathway of the complement system may
play an important role in retinal immunity.
Our  observation  of  the  complement  gene  expression
profile on murine retina and RPE/choroid is in agreement with
a recent study in man by Anderson et al. [6] in which the
authors  reported  that  human  retina,  choroid,  and  RPE
expressed  a  variety  of  CP-  and  AP-related  complement/
complement regulatory genes [6]. Genes of the MBL pathway
were only expressed at background levels [6]. In addition, our
observation on cultured murine RPE cells is also similar to
that of cultured human fetal RPE cells [6], with the exception
of C5. A low level of C5 gene expression was detected in
human retina and RPE cells by real-time RT–PCR [6]. In
contrast, in our study C5 gene expression was not detected in
either primary cultured mouse RPE cells or the mouse RPE
cell line B6-RPE07 cells (Figure 4B) nor was it induced by
cytokines  IL-6,  TNF-α,  and  INF-γ.  It  is  possible  that  the
discrepancy between humans and mice in relation to C5 gene
expression by RPE cells may reflect a species difference. For
example, a previous study in murine brain tissue has shown
that C5 was only detectable in the cerebellum of malaria-
infected but not normal mouse [29]. However, in humans
C5 was detected in several regions of the brain [30] as well as
in brain oligodendroglial cells at both mRNA and protein
levels [31].
In this study, we find that complement gene expression
in microglia and RPE cells is regulated predominately by
inflammatory cytokines IFN-γ and TNF-α and is less affected
by IL-6 and LPS. Increased production of IFN-γ or TNF-α has
been observed in uveoretinitis [32,33], diabetic retinopathy
[34-36], and age-related macular degeneration [37]. In the
normal aging retina, TNF-α gene expression is increased as
compared to young retina [38]. Complement activation has
Figure 7. The effect of inflammatory cytokine on alternative pathway-related complement gene expression in BV-2 and retinal pigment
epithelium cells. Primary RPE cells and BV-2 cells were treated with pro-inflammatory cytokines TNF-α (20 ng/ml), interferon (IFN)-γ (100
ng/ml), interleukin (IL)-6 (10 ng/ml), and lipopolysaccharides (LPS; 1 µg/ml) for 20 h. Cells were then collected for real-time RT–PCR (A)
or conventional RT–PCR (B). Mouse liver RNA was used as a positive control in B. A: The effect of inflammatory cytokines on CFH and
CFB genes expression in BV-2 cells. B: The effect of inflammatory cytokines on CFI and CFHR1 gene expression in BV-2 and RPE cells.
n=3 in each group. *p<0.05 when compared to untreated control group using unpaired Student's t test. Experiments were repeated twice.
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1594been  shown  to  be  involved  in  the  aforementioned  retinal
diseases  [5,9-13,15-17]  and  in  normal  retinal  aging  [21].
Macrophages and microglial cells are the major sources of
inflammatory cytokine production in the retina. Our result
suggests that the two major components of the retinal innate
immune  system,  i.e.,  the  myeloid-derived  cells  and  the
complement  system,  may  work  together  under
pathophysiologic conditions. On the one hand, inflammatory
cytokines produced by activated microglial cells or infiltrating
macrophages may increase CP- and AP-complement gene
expression, leading to retinal complement activation. On the
other hand, complement activation may release complement
fragments C3a and C5a, which may further affect microglia
or macrophage activation and migration.
In  addition  to  myeloid-derived  cells,  RPE  cells  also
actively  interact  with  the  complement  system.  RPE  cells
express and produce a variety of complement components
[6,20,21,39].  Activated  RPE  cells  also  produce  various
inflammatory cytokines [40-44], which may affect their own
complement gene expression. Complement activation, on the
other  hand,  may  affect  RPE  function.  For  example,
complement fragment C5a is able to induce inflammatory
cytokines IL-1β,IL-6,CCL2,IL-8 [43], and VEGF expression
in RPE cells [45].
Therefore, retinal microglial cells, RPE cells, and the
complement system, comprising the retinal innate immune
system, may play an important role in retinal homeostasis.
Under overt inflammatory conditions, they may interact with
the  adaptive  immune  system,  contributing  to  retinal
pathologies.  Experimental  autoimmune  uveoretinitis,  for
example, is a Th1-type autoimmune disease [46,47], and the
disease  is  characterized  by  macrophage  and  CD4  T-cell
infiltration together with high levels of IFN-γ and TNF-α
production  [32,33].  Recent  studies  have  shown  that
complement activation [11], particularly that mediated by the
AP,  significantly  contributes  to  retinal  pathology  in
experimental autoimmune uveoretinitis [38,48]. In this study,
we show that IFN-γ strongly upregulates the CP- and AP-
related  genes  (>600  fold  increase  in  the  CFB  gene  in
microglial cells (Figure 7), suggesting that IFN-γ may play an
important  role  in  retinal  complement  activation  in
uveoretinitis.
In summary, our data suggest that the CP and AP are
likely to be the main pathways involved in retinal complement
Figure 8. The effect of inflammatory cytokine on complement C3 and C5 gene expression in BV-2 and retinal pigment epithelium cells.
Primary RPE cells and BV-2 cells were treated with pro-inflammatory cytokines tumor necrosis factor (TNF)-α (20 ng/ml), interferon (IFN)-
γ (100 ng/ml), interleukin (IL)-6 (10 ng/ml), and lipopolysaccharides (LPS;1 µg/ml) for 20 h. Cells were then collected for real-time RT–PCR
analysis of C3 gene expression (A) or conventional RT–PCR analysis of C5 gene expression (B). Mouse liver RNA was used as a positive
control in B. n=3 in each group. *p<0.05; **p<0.01 when compared to untreated controls using unpaired Student's t test. Experiments were
repeated twice.
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1595activation and that RPE and retinal microglial cells contribute
significantly  to  related  complement  gene  expression.  In
addition,  our  findings  also  suggest  that  the  tissue
microenvironment, particularly the inflammatory cytokines
present,  may  play  critical  roles  in  controlling  retinal
complement gene expression. However, further knowledge
relating to how the retinal microenvironment may affect the
expression and activation of the complement system under
different pathological conditions is essential to understand the
role of the complement system in different disease conditions,
such  as  age-related  macular  degeneration,  diabetic
retinopathy, and glaucoma.
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